Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.

ABSTRACT: Integrated whole genome and transcriptome sequencing can unveil distinct molecular subgroups in pancreatic cancer (PDAC). The COMPASS trial (NCT02750657) enrolled 268 patients with advanced PDAC; patients were given either modified (m) FOLFIRINOX or Gemcitabine-nab-paclitaxel (GnP) as per physicians choice. Median follow-up is 52 months and median overall survival in those receiving mFOLFIRINOX is 10.6 months and 8.4 months for GnP. KRAS specific mutants and allelic states alone are not prognostic; however basal-like PDAC are more likely to harbour major imbalances in mutant KRAS (KRAS^maj). In the presence of KRAS^maj, pre-existing type II DM is more common. Distinct prognostic cohorts include homologous-recombination deficient PDAC, predictive of mFOLFIRINOX response.

SUBMITTER: Knox JJ 

PROVIDER: S-EPMC12219293 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature